Researchers in the United Kingdom have completed initial human trials of a vaccine technology that eliminates the need for constant refrigeration, addressing a significant challenge in global vaccine distribution. The innovation centers on converting liquid vaccines into dry powder form that remains stable at room temperature, then reconstituting them with water before administration.
The trial enrolled 60 volunteers to test a tetanus-diphtheria vaccine processed using trehalose, a sugar compound naturally produced by resurrection plants. These plants survive droughts by producing trehalose, which protects their cellular structures during extreme desiccation. Researchers adapted this biological mechanism to stabilize vaccine components, allowing the tetanus-diphtheria formulation to remain viable for a year at room temperature. Trial results demonstrated that the dried vaccine produced immune responses equivalent to conventional refrigerated versions while proving safe and well-tolerated in early-stage studies.
The current vaccine storage approach, known as the “cold chain,” requires precise temperature control from manufacture through administration. This system presents particular challenges in resource-limited regions and conflict zones where reliable electricity and refrigeration infrastructure remain scarce. The World Health Organization estimates that approximately half of all vaccines globally are wasted annually, with cold chain failures representing a substantial portion of this loss.
A larger trial involving 160 participants is scheduled to begin in the coming months. Because the original tetanus-diphtheria vaccine already holds regulatory approval, this expanded study will serve as the final research phase rather than requiring the extensive trials typically mandated for novel vaccine candidates. Researchers report that vaccine components also withstand temperature cycling between -20 degrees Celsius and +40 degrees Celsius, suggesting potential viability even after exposure to varying conditions during transport.
While the technology shows promise for numerous existing vaccines and some medicines such as monoclonal antibodies, it cannot currently be applied to newer mRNA vaccine platforms. Additional investigation remains necessary regarding vaccine stability under repeated temperature fluctuations and performance across larger and more ethnically diverse population groups. The findings have been published in eClinicalMedicine, part of the Lancet publishing group.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI